MQ’s sales trend was strong during the third quarter when sales in comparable stores/online increased 4.3 percent. According to the Swedish Retail Institute Index (HUI), the market for like-for-like sales declined 3.4 percent in the same period. Continued strengthening of the product range with more brands and a higher degree of fashion content have advanced MQ’s fashion position. Earnings continue to develop positively and the net debt is historically low. It is gratifying to state that the development work is generating results on several levels. Third quarter (March 2015–May 2015) · Net sales amounted to SEK 363 million (350), up 3.7 percent. Sales in comparable stores/online rose 4.3 percent (the market’s like-for-like sales declined 3.4 percent according to the Swedish Retail Institute Index). · The gross margin was 60.1 percent (61.3). · Operating profit amounted to SEK 47 million (42), corresponding to an operating margin of 12.8 percent (12.0). · Profit after tax was SEK 36 million (31), corresponding to SEK 1.01 (0.90) per share after dilution. · Cash flow from operating activities was SEK 46 million (63). Nine-month period (September 2014-May 2015) · Net sales amounted to SEK 1,137 million (1,139), down 0.2 percent. Sales in comparable stores/online rose 0.7 percent (the market’s like-for-like sales declined 1.7 percent according to the Swedish Retail Institute Index). · The gross margin was 56.7 percent (56.6). · Operating profit amounted to SEK 111 million (97), corresponding to an operating margin of 9.8 percent (8.6). · Profit after tax was SEK 84 million (70), corresponding to SEK 2.39 (2.02) per share after dilution. · Cash flow from operating activities totalled SEK 115 million (118). Events during the third quarter · MQ Shop Online was launched in the Norwegian market in March. · The external brands Part Two, Bruuns Bazaar BZR and Dry Lake were launched on MQ Shop Online. Events after the end of the reporting period · No events occurred after the end of the reporting period. For further information, please contact: Christina Ståhl, President and CEO: Tel: +46 (0)31 388 80 10 Tony Siberg, Deputy CEO and CFO: Tel: +46 (0)31 388 84 01 MQ is Sweden’s leading brand chain. Through a select mix of proprietary and external brands, MQ offers men’s and women’s clothes with a high fashion content in attractive stores. The store chain currently comprises 120 stores and the aim is to establish MQ as the leading retailer of fashion brands in the Nordic region. The MQ share has been listed on NASDAQ Stockholm since 18 June 2010. For more information, please visit our website at www.mq.se.
Strong sales growth in the quarter MQ’s sales trend was
Top 10 Most Recent News Articles
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices
A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments
Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....
Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue ReadingTop 5 Most Recently Viewed Articles
Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa
Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...
Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV
Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...
Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial
Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...
Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future
Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...
Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley
B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...
Continue Reading